BioMarin Pharmaceutical Statistics
Total Valuation
BMRN has a market cap or net worth of $10.26 billion. The enterprise value is $9.39 billion.
| Market Cap | 10.26B |
| Enterprise Value | 9.39B |
Important Dates
The last earnings date was Monday, October 27, 2025, after market close.
| Earnings Date | Oct 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BMRN has 192.11 million shares outstanding. The number of shares has increased by 2.10% in one year.
| Current Share Class | 192.11M |
| Shares Outstanding | 192.11M |
| Shares Change (YoY) | +2.10% |
| Shares Change (QoQ) | -2.57% |
| Owned by Insiders (%) | 0.78% |
| Owned by Institutions (%) | 96.15% |
| Float | 190.43M |
Valuation Ratios
The trailing PE ratio is 19.92 and the forward PE ratio is 11.13. BMRN's PEG ratio is 0.58.
| PE Ratio | 19.92 |
| Forward PE | 11.13 |
| PS Ratio | 3.30 |
| Forward PS | 3.03 |
| PB Ratio | 1.69 |
| P/TBV Ratio | 1.82 |
| P/FCF Ratio | 12.33 |
| P/OCF Ratio | 11.22 |
| PEG Ratio | 0.58 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.82, with an EV/FCF ratio of 11.28.
| EV / Earnings | 18.03 |
| EV / Sales | 3.03 |
| EV / EBITDA | 11.82 |
| EV / EBIT | 13.19 |
| EV / FCF | 11.28 |
Financial Position
The company has a current ratio of 4.83, with a Debt / Equity ratio of 0.10.
| Current Ratio | 4.83 |
| Quick Ratio | 2.84 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.75 |
| Debt / FCF | 0.73 |
| Interest Coverage | 66.49 |
Financial Efficiency
Return on equity (ROE) is 9.07% and return on invested capital (ROIC) is 7.01%.
| Return on Equity (ROE) | 9.07% |
| Return on Assets (ROA) | 6.15% |
| Return on Invested Capital (ROIC) | 7.01% |
| Return on Capital Employed (ROCE) | 10.44% |
| Revenue Per Employee | $1.02M |
| Profits Per Employee | $171,190 |
| Employee Count | 3,040 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 0.45 |
Taxes
In the past 12 months, BMRN has paid $158.86 million in taxes.
| Income Tax | 158.86M |
| Effective Tax Rate | 23.39% |
Stock Price Statistics
The stock price has decreased by -19.71% in the last 52 weeks. The beta is 0.30, so BMRN's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | -19.71% |
| 50-Day Moving Average | 53.83 |
| 200-Day Moving Average | 58.77 |
| Relative Strength Index (RSI) | 46.22 |
| Average Volume (20 Days) | 3,031,854 |
Short Selling Information
The latest short interest is 8.95 million, so 4.66% of the outstanding shares have been sold short.
| Short Interest | 8.95M |
| Short Previous Month | 9.86M |
| Short % of Shares Out | 4.66% |
| Short % of Float | 4.70% |
| Short Ratio (days to cover) | 3.28 |
Income Statement
In the last 12 months, BMRN had revenue of $3.09 billion and earned $520.42 million in profits. Earnings per share was $2.68.
| Revenue | 3.09B |
| Gross Profit | 2.52B |
| Operating Income | 711.32M |
| Pretax Income | 679.27M |
| Net Income | 520.42M |
| EBITDA | 794.05M |
| EBIT | 711.32M |
| Earnings Per Share (EPS) | $2.68 |
Balance Sheet
The company has $1.48 billion in cash and $604.24 million in debt, giving a net cash position of $873.60 million or $4.55 per share.
| Cash & Cash Equivalents | 1.48B |
| Total Debt | 604.24M |
| Net Cash | 873.60M |
| Net Cash Per Share | $4.55 |
| Equity (Book Value) | 6.06B |
| Book Value Per Share | 31.53 |
| Working Capital | 3.06B |
Cash Flow
In the last 12 months, operating cash flow was $913.98 million and capital expenditures -$81.85 million, giving a free cash flow of $832.13 million.
| Operating Cash Flow | 913.98M |
| Capital Expenditures | -81.85M |
| Free Cash Flow | 832.13M |
| FCF Per Share | $4.33 |
Margins
Gross margin is 81.32%, with operating and profit margins of 22.99% and 16.82%.
| Gross Margin | 81.32% |
| Operating Margin | 22.99% |
| Pretax Margin | 21.95% |
| Profit Margin | 16.82% |
| EBITDA Margin | 25.66% |
| EBIT Margin | 22.99% |
| FCF Margin | 26.89% |
Dividends & Yields
BMRN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.10% |
| Shareholder Yield | -2.10% |
| Earnings Yield | 5.07% |
| FCF Yield | 8.11% |
Analyst Forecast
The average price target for BMRN is $88.42, which is 65.58% higher than the current price. The consensus rating is "Buy".
| Price Target | $88.42 |
| Price Target Difference | 65.58% |
| Analyst Consensus | Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (5Y) | 6.88% |
| EPS Growth Forecast (5Y) | 23.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BMRN has an Altman Z-Score of 5.84 and a Piotroski F-Score of 7.
| Altman Z-Score | 5.84 |
| Piotroski F-Score | 7 |